Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity

Ahmed El-Boraie, Taraneh Taghavi, Meghan J. Chenoweth, Koya Fukunaga, Taisei Mushiroda, Michiaki Kubo, Caryn Lerman, Nicole L. Nollen, Neal L. Benowitz, Rachel F. Tyndale

Research output: Contribution to journalArticle

Abstract

The nicotine metabolite ratio (NMR; 3-hydroxycotinine/cotinine) is an index of CYP2A6 activity. CYP2A6 is responsible for nicotine's metabolic inactivation and variation in the NMR/CYP2A6 is associated with several smoking behaviors. Our aim was to integrate established alleles and novel genome-wide association studies (GWAS) signals to create a weighted genetic risk score (wGRS) for the CYP2A6 gene for European-ancestry populations. The wGRS was compared with a previous CYP2A6 gene scoring approach designed for an alternative phenotype (C2/N2; cotinine-d2/(nicotine-d2 + cotinine-d2)). CYP2A6 genotypes and the NMR were assessed in European-ancestry participants. The wGRS training set included N = 933 smokers recruited to the Pharmacogenetics of Nicotine Addiction and Treatment clinical trial [NCT01314001]. The replication cohort included N = 196 smokers recruited to the Quit 2 Live clinical trial [NCT01836276]. Comparisons between the two CYP2A6 phenotypes and with fractional clearance were made in a laboratory-based pharmacokinetic study (N = 92 participants). In both the training and replication sets, the wGRS, which included seven CYP2A6 variants, explained 33.8% (P < 0.001) of the variance in NMR, providing improved predictive power to the NMR phenotype when compared with other CYP2A6 gene scoring approaches. NMR and C2/N2 were strongly correlated to nicotine clearance (ρ = 0.70 and ρ = 0.79, respectively; P < 0.001), and to one another (ρ = 0.82; P < 0.001); however reduced function genotypes occurred in slow NMR but throughout C2/N2. The wGRS was able to predict smoking quantity and nicotine intake, to discriminate between NMR slow and normal metabolizers (AUC = 0.79; P < 0.001), and to replicate previous NMR-stratified cessation outcomes showing unique treatment outcomes between metabolizer groups.

Original languageEnglish
JournalAddiction Biology
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Nicotine
Biomarkers
Cotinine
Phenotype
Smoking
Genotype
Clinical Trials
Genes
Genome-Wide Association Study
Pharmacogenetics
Area Under Curve
Pharmacokinetics
Alleles
Population

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology
  • Psychiatry and Mental health

Cite this

El-Boraie, A., Taghavi, T., Chenoweth, M. J., Fukunaga, K., Mushiroda, T., Kubo, M., ... Tyndale, R. F. (2019). Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. Addiction Biology. https://doi.org/10.1111/adb.12741
El-Boraie, Ahmed ; Taghavi, Taraneh ; Chenoweth, Meghan J. ; Fukunaga, Koya ; Mushiroda, Taisei ; Kubo, Michiaki ; Lerman, Caryn ; Nollen, Nicole L. ; Benowitz, Neal L. ; Tyndale, Rachel F. / Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. In: Addiction Biology. 2019.
@article{5cafbfd3af1143dbaaafdbc87459fd81,
title = "Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity",
abstract = "The nicotine metabolite ratio (NMR; 3-hydroxycotinine/cotinine) is an index of CYP2A6 activity. CYP2A6 is responsible for nicotine's metabolic inactivation and variation in the NMR/CYP2A6 is associated with several smoking behaviors. Our aim was to integrate established alleles and novel genome-wide association studies (GWAS) signals to create a weighted genetic risk score (wGRS) for the CYP2A6 gene for European-ancestry populations. The wGRS was compared with a previous CYP2A6 gene scoring approach designed for an alternative phenotype (C2/N2; cotinine-d2/(nicotine-d2 + cotinine-d2)). CYP2A6 genotypes and the NMR were assessed in European-ancestry participants. The wGRS training set included N = 933 smokers recruited to the Pharmacogenetics of Nicotine Addiction and Treatment clinical trial [NCT01314001]. The replication cohort included N = 196 smokers recruited to the Quit 2 Live clinical trial [NCT01836276]. Comparisons between the two CYP2A6 phenotypes and with fractional clearance were made in a laboratory-based pharmacokinetic study (N = 92 participants). In both the training and replication sets, the wGRS, which included seven CYP2A6 variants, explained 33.8{\%} (P < 0.001) of the variance in NMR, providing improved predictive power to the NMR phenotype when compared with other CYP2A6 gene scoring approaches. NMR and C2/N2 were strongly correlated to nicotine clearance (ρ = 0.70 and ρ = 0.79, respectively; P < 0.001), and to one another (ρ = 0.82; P < 0.001); however reduced function genotypes occurred in slow NMR but throughout C2/N2. The wGRS was able to predict smoking quantity and nicotine intake, to discriminate between NMR slow and normal metabolizers (AUC = 0.79; P < 0.001), and to replicate previous NMR-stratified cessation outcomes showing unique treatment outcomes between metabolizer groups.",
author = "Ahmed El-Boraie and Taraneh Taghavi and Chenoweth, {Meghan J.} and Koya Fukunaga and Taisei Mushiroda and Michiaki Kubo and Caryn Lerman and Nollen, {Nicole L.} and Benowitz, {Neal L.} and Tyndale, {Rachel F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/adb.12741",
language = "English",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",

}

El-Boraie, A, Taghavi, T, Chenoweth, MJ, Fukunaga, K, Mushiroda, T, Kubo, M, Lerman, C, Nollen, NL, Benowitz, NL & Tyndale, RF 2019, 'Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity', Addiction Biology. https://doi.org/10.1111/adb.12741

Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. / El-Boraie, Ahmed; Taghavi, Taraneh; Chenoweth, Meghan J.; Fukunaga, Koya; Mushiroda, Taisei; Kubo, Michiaki; Lerman, Caryn; Nollen, Nicole L.; Benowitz, Neal L.; Tyndale, Rachel F.

In: Addiction Biology, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity

AU - El-Boraie, Ahmed

AU - Taghavi, Taraneh

AU - Chenoweth, Meghan J.

AU - Fukunaga, Koya

AU - Mushiroda, Taisei

AU - Kubo, Michiaki

AU - Lerman, Caryn

AU - Nollen, Nicole L.

AU - Benowitz, Neal L.

AU - Tyndale, Rachel F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The nicotine metabolite ratio (NMR; 3-hydroxycotinine/cotinine) is an index of CYP2A6 activity. CYP2A6 is responsible for nicotine's metabolic inactivation and variation in the NMR/CYP2A6 is associated with several smoking behaviors. Our aim was to integrate established alleles and novel genome-wide association studies (GWAS) signals to create a weighted genetic risk score (wGRS) for the CYP2A6 gene for European-ancestry populations. The wGRS was compared with a previous CYP2A6 gene scoring approach designed for an alternative phenotype (C2/N2; cotinine-d2/(nicotine-d2 + cotinine-d2)). CYP2A6 genotypes and the NMR were assessed in European-ancestry participants. The wGRS training set included N = 933 smokers recruited to the Pharmacogenetics of Nicotine Addiction and Treatment clinical trial [NCT01314001]. The replication cohort included N = 196 smokers recruited to the Quit 2 Live clinical trial [NCT01836276]. Comparisons between the two CYP2A6 phenotypes and with fractional clearance were made in a laboratory-based pharmacokinetic study (N = 92 participants). In both the training and replication sets, the wGRS, which included seven CYP2A6 variants, explained 33.8% (P < 0.001) of the variance in NMR, providing improved predictive power to the NMR phenotype when compared with other CYP2A6 gene scoring approaches. NMR and C2/N2 were strongly correlated to nicotine clearance (ρ = 0.70 and ρ = 0.79, respectively; P < 0.001), and to one another (ρ = 0.82; P < 0.001); however reduced function genotypes occurred in slow NMR but throughout C2/N2. The wGRS was able to predict smoking quantity and nicotine intake, to discriminate between NMR slow and normal metabolizers (AUC = 0.79; P < 0.001), and to replicate previous NMR-stratified cessation outcomes showing unique treatment outcomes between metabolizer groups.

AB - The nicotine metabolite ratio (NMR; 3-hydroxycotinine/cotinine) is an index of CYP2A6 activity. CYP2A6 is responsible for nicotine's metabolic inactivation and variation in the NMR/CYP2A6 is associated with several smoking behaviors. Our aim was to integrate established alleles and novel genome-wide association studies (GWAS) signals to create a weighted genetic risk score (wGRS) for the CYP2A6 gene for European-ancestry populations. The wGRS was compared with a previous CYP2A6 gene scoring approach designed for an alternative phenotype (C2/N2; cotinine-d2/(nicotine-d2 + cotinine-d2)). CYP2A6 genotypes and the NMR were assessed in European-ancestry participants. The wGRS training set included N = 933 smokers recruited to the Pharmacogenetics of Nicotine Addiction and Treatment clinical trial [NCT01314001]. The replication cohort included N = 196 smokers recruited to the Quit 2 Live clinical trial [NCT01836276]. Comparisons between the two CYP2A6 phenotypes and with fractional clearance were made in a laboratory-based pharmacokinetic study (N = 92 participants). In both the training and replication sets, the wGRS, which included seven CYP2A6 variants, explained 33.8% (P < 0.001) of the variance in NMR, providing improved predictive power to the NMR phenotype when compared with other CYP2A6 gene scoring approaches. NMR and C2/N2 were strongly correlated to nicotine clearance (ρ = 0.70 and ρ = 0.79, respectively; P < 0.001), and to one another (ρ = 0.82; P < 0.001); however reduced function genotypes occurred in slow NMR but throughout C2/N2. The wGRS was able to predict smoking quantity and nicotine intake, to discriminate between NMR slow and normal metabolizers (AUC = 0.79; P < 0.001), and to replicate previous NMR-stratified cessation outcomes showing unique treatment outcomes between metabolizer groups.

UR - http://www.scopus.com/inward/record.url?scp=85062332691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062332691&partnerID=8YFLogxK

U2 - 10.1111/adb.12741

DO - 10.1111/adb.12741

M3 - Article

AN - SCOPUS:85062332691

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

ER -